Target Price | ¥1,377.00 |
Price | ¥1,887.00 |
Deviation |
27.03%
register free of charge
|
Number of Estimates | 9 |
9 Analysts have issued a price target Sumitomo Dainippon Pharma 2026 .
The average Sumitomo Dainippon Pharma target price is ¥1,377.00.
This is
27.03%
register free of charge
¥1,995.00
5.72%
register free of charge
¥656.50
65.21%
register free of charge
|
|
A rating was issued by 11 analysts: 6 Analysts recommend Sumitomo Dainippon Pharma to buy, 3 to hold and 2 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Sumitomo Dainippon Pharma stock has an average upside potential 2026 of
27.03%
register free of charge
|
Mar '25 |
2026 Estimates |
|
---|---|---|
Revenue Billion ¥ | 398.83 | 421.82 |
26.79% | 5.76% | |
EBITDA Margin | 9.70% | 25.97% |
121.51% | 167.61% | |
Net Margin | 5.93% | 15.52% |
105.92% | 161.91% |
8 Analysts have issued a sales forecast Sumitomo Dainippon Pharma 2026 . The average Sumitomo Dainippon Pharma sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Sumitomo Dainippon Pharma EBITDA forecast 2026. The average Sumitomo Dainippon Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Sumitomo Dainippon Pharma Analysts have issued a net profit forecast 2026. The average Sumitomo Dainippon Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Mar '25 |
2026 Estimates |
|
---|---|---|
Earnings Per Share ¥ | 59.49 | 164.83 |
107.50% | 177.07% | |
P/E | 11.45 | |
EV/Sales | 2.42 |
8 Analysts have issued a Sumitomo Dainippon Pharma forecast for earnings per share. The average Sumitomo Dainippon Pharma EPS is
This results in the following potential growth metrics and future valuations:
Sumitomo Dainippon Pharma...
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.